期刊文献+

特制人工膝关节假体在骨肉瘤合并病理骨折保肢治疗中的应用 被引量:3

Application of custom-manufactured artificial total knee prosthesis in limb salvage surgery for patients with a pathologic fracture in osteosarcoma
下载PDF
导出
摘要 背景:骨肉瘤合并病理性骨折以往采用截肢治疗。随着新辅助化疗的临床应用,人工假体制作工艺和材料的改进,部分骨肉瘤合并病理性骨折的患者获得了保肢治疗的可能。目的:探讨特制人工膝关节假体置换在骨肉瘤合并病理性骨折保肢治疗中的效果。方法:2002年6月至2012年9月共收治11例临近膝关节骨肉瘤合并病理性骨折患者,根据患者的个体情况定制肿瘤膝关节假体行保肢治疗,对其随访结果进行回顾性分析。其中男6例(54.5%),女5例(45.5%);年龄11-50岁,平均25.4岁;发病部位:股骨远端7例,胫骨近端4例。所有患者均接受新辅助化疗并应用特制膝关节假体行保肢治疗,随访时间9-105个月。结果与结论:11例患者假体置换后局部复发率为18%,肺转移率为36%,5年生存率为58%。4例患者发生肺转移,死亡时间为假体置换后9-24个月。末次随访患肢Enneking评分11-30分,平均23.3分,优良率为82%。提示应用特制膝关节假体置换联合新辅助化疗方案,对膝关节周围骨肉瘤合并病理骨折患者行保肢治疗近期效果理想,远期疗效尚需评价。 BACKGROUND:Osteosarcoma combined with pathological fracture was often treated by amputation. With clinical application of neoadjuvant chemotherapy and improvement of technology and material of the prosthesis, the limbs of patients with osteosarcoma combined with pathological fracture were reserved. OBJECTIVE:To evaluate the effect of the application of custom-manufactured artificial total knee prosthesis replacement in limb salvage treatment for patients with osteosarcoma combined with pathological fracture. METHODS:A total of 11 patients with pathological fracture with osteosarcoma located in adjacent knee Joint were enrol ed from June 2002 to September 2012. In accordance with individual condition of the patient, limb salvage treatment was designed for knee prosthesis for a tumor. Fol ow-up results were retrospectively analyzed. There were six males (54.5%) and five females (45.5%) and their age ranged from 11 to 50 years old with an average age of 25.4 years old. Onset regions:seven tumors were located in the distal femur and four tumors were in the proximal tibia. Al patients received neoadjuvant chemotherapy, and limb salvage treatment with custom-manufactured artificial knee prosthesis. The fol ow up was performed for 9 to 105 months. RESULTS AND CONCLUSION:In 11 patients after prosthesis replacement, the regional recurrence rates were 18%, lung metastasis rates were 36%. The five-year survival rate was 58%. Four patients developed lung metastases and died in 9 to 24 months postoperatively. During the last fol ow-up, Enneking score of the affected limbs was 11 to 30 points, averagely 23.3 points, with an excellent and good rate of 82%. Results indicated that combined with neoadjuvanet chemotherapy, the application of custom-manufactured artificial total knee prosthesis replacement in the treatment of osteosarcoma located in adjacent knee joint and pathological fracture achieved an ideal outcomes of the limb salvage treatment in the near future. The lone-term effectiveness was expected to be evaluated.
出处 《中国组织工程研究》 CAS CSCD 2014年第26期4131-4135,共5页 Chinese Journal of Tissue Engineering Research
关键词 植入物 人工假体 骨肉瘤 病理骨折 保肢 prosthesis implantation osteosarcoma fractures,bone retrospective studies
  • 相关文献

参考文献17

  • 1Bacci G,Farrm'i S,Longhi A. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation:local and systemic control by amputation or limb salvage after preoperative chemotherapy[J].Acta Orthopaedica Scandinavica,2003.449-454.
  • 2Abudu A,Sferopoulos NK,Til man RM. The surgical treat-ment and outcome of pathological fractures in localised osteosarcoma[J].JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME,1996,(05):694-698.
  • 3Malagelada F,Tarrago LT,Tibrewal S. Pathological Fracture in Osteosarcoma:Is it Always an Indication for Amputation Ortop Traumatol Rehabil[J].2014,(01):67-74.
  • 4Xie L,Guo W,Li Y. Pathologic fracture does not influence local recurrence and survival in high-grade extremity osteosarcoma with adequate surgical margins[J].Journal of Surgical Oncology,2012,(07):820-825.
  • 5Bramer JA,Abudu AA,Grimer RJ. Do pathological fractures influence survivaI and IocaI recurrence rate in bony sarcomas[J].EUROPEAN JOURNAL OF CANCER,2007.1944-1951.
  • 6Jones KB1,Ferguson PC,Lam B. Effects of neoadjuvant chemotherapy on image-directed planning of surgical resection for distal femoral osteosarcoma[J].Journal of Bone and Joint Surgery-American Volume,2012,(15):1399-1405.
  • 7Ferguson PC,McLaughlin CE,Griffin AM. Clinical and functional outcomes of patients with a pathologic fracture in high-grade osteosarcoma[J].Journal of Surgical Oncology,2010,(02):120-124.
  • 8Ritter J,Bielack SS. Osteosarcoma[J].ANNALS OF ONCOLOGY,2010,(Suppl 7):320-325.
  • 9Kim MS,Lee SY,Lee TR. Prognostic effect of pathologic fracture in localized osteosarcoma:a cohort/case control ed study at a single institute[J].Journal of Surgical Oncology,2009,(03):233-239.
  • 10罗仁峰,何安兵,陈春洲.新辅助化疗联合保肢治疗骨肉瘤合并病理性骨折[J].中华创伤杂志,2013,29(4):334-337. 被引量:10

二级参考文献18

  • 1牛晓辉,蔡槱伯,张清,郝林,丁易.ⅡB期肢体骨肉瘤189例综合治疗临床分析[J].中华外科杂志,2005,43(24):1576-1579. 被引量:41
  • 2Baeci G, Farrari S, Longhi A, et at. Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation : local and systemic control by amputation or limb salvage after preoperative chemotherapy. Acta Orthop Scand, 2003, 74:449-454.
  • 3Scully SP, Temple HT, O'Keefe RJ, et al. The surgical treatment of patients with osteosarcoma who sustain a pathologic fracture. Clin Orthop Relat Res, 1996(324) :227-232.
  • 4Abudu A, Sferopoulos NK, Tillman RM, et al. The surgical treatment and outcome of pathological fractures in localised osteosarcoma. J Bone Joint Surg Br, 1996, 78:694-698.
  • 5Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand, 1998, 69:230-236.
  • 6Scully SP, Ghert MA, Zurakowski D, et al. Pathologic fracture in osteosarcoma: prognostic importance and treatment implications. J Bone Joint Surg Am, 2002, 84:49-57.
  • 7Saifnddin A. The accuracy of imaging in the local staging of appendicular osteosarcoma. Skeletal Radio, 2002, 31 : 194-201.
  • 8Bielack SS, Kempf-Bielack B, Winkler K. Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol,1996, 14:683-684.
  • 9Rosen G, Caparros B, Huvos AG, et al. Preoperative chemothera- py for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preop- erative chemotherapy. Cancer, 2002, 49 (6) : 1221 - 1230.
  • 10Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer, 2011,47(16) :2431 -2445.

共引文献12

同被引文献37

  • 1牛晓辉,蔡槱伯,张清,郝林,丁易.ⅡB期肢体骨肉瘤189例综合治疗临床分析[J].中华外科杂志,2005,43(24):1576-1579. 被引量:41
  • 2林丽珠,周京旭,张恩欣,黄海福.恩度联合含培美曲塞方案治疗复发耐药骨肉瘤2例[J].中国肿瘤临床,2007,34(20):1197-1199. 被引量:15
  • 3Zhang P,Yang Y,Zweidler-Mckay P,et al.Retraction:Critical Role of Notch Signaling in Osteosarcoma Invasion and Metastasis[J].Clin Cancer Res,2013,19(18):5256.
  • 4Luetke A,Meyers P A,Lewis I,et al.Osteosarcoma treatment-where do we stand A state of the art review[J].Cancer Treat Rev,2014,40(4):523.
  • 5Ando K.Current Therapeutic Strategies and Novel Approaches in Osteosarcoma[J].Cancers,2013,5(2):591.
  • 6Hughes D P M,Thomas D G,Giordano T J,et al.Essential erb B family phosphorylation in osteosarcoma as a target for CI-1033 inhibition[J].Pediatr Blood Cancer,2013,60(1):614.
  • 7Dass C R,Contreras K G,Dunstan D E,et al.Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma[J].Biomaterials,2007,28(19):3026.
  • 8Liu O,Ping L,Yang S,et al.A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma[J].Med Oncol,2013,30(1):758.
  • 9胡玉华,茹江英,胡传亮,徐长明,王长峰,杜广军,姜景辉.膝关节周围骨折合并血管神经损伤早期诊断与治疗[J].中国骨与关节损伤杂志,2008,23(7):533-535. 被引量:6
  • 10温海华,杨晓宁.骨肉瘤非手术治疗新进展[J].中外医疗,2009,28(27):17-18. 被引量:3

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部